慢性心力衰竭患者的共病与多重用药:初级保健大规模横断面研究
该研究基于苏格兰初级保健数据库1 424 378名成人,比较左室收缩功能不全(LVSD)所致慢性心衰患者与非心衰患者的共病和多重用药情况。结果显示LVSD患者共病和多重用药显著更常见,但多重用药差异在控制 morbility 数量后减弱,提示额外处方多由多病共存而非LVSD本身解释。
要点
- LVSD患者共病负担更重,≥7种共病风险显著升高(OR 4.10)。
- LVSD患者多重用药更常见,≥11种重复处方风险升高(OR 4.81)。
- 控制共病数量后多重用药差异减弱,提示处方负担主要由多病共存驱动。
核心结论
- LVSD所致慢性心衰患者极端共病和多重用药显著更常见,管理需整合全科与专科能力。
研究设计与样本
- 基于苏格兰初级保健数据库1 424 378名成人的横断面研究,比较LVSD患者与非LVSD患者的共病和用药情况。
主要发现
- 17 285名(1.2%)患者诊断为LVSD。
- 相比标准化对照,LVSD组共病更多,≥7种共病的OR为4.10(95%CI 3.90–4.32)。
- LVSD组≥11种重复处方的OR为4.81(95%CI 4.60–5.04)。
- 控制共病数量后,多重用药差异减弱,提示额外处方多由多病共存而非LVSD本身解释。
关键数值与推荐
- 共病比较涵盖31种其他躯体疾病和7种精神健康疾病。
- 共病和多重用药 prevalence 按年龄、性别和剥夺程度标准化。
临床怎么用
- 全科医生应主动评估LVSD心衰患者的共病和多重用药负担。
- 管理复杂共病和多重用药需整合全科与专科 expertise。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Comorbidity is common in heart failure, but previous prevalence estimates have been based on a limited number of conditions using mainly non-primary care data sources. AIM: To compare prevalence rates of comorbidity and polypharmacy in those with and without chronic heart failure due to left ventricular systolic dysfunction (LVSD). DESIGN AND SETTING: A cross-sectional study of 1.4 million patients in primary care in Scotland. METHOD: Data on the presence of LVSD, 31 other physical, and seven mental health comorbidities, and prescriptions were extracted from a database of 1 424 378 adults. Comorbidity prevalence was compared in patients with and without LVSD, standardised by age, sex, and deprivation. Pharmacology data were also compared between the two groups. RESULTS: There were 17 285 patients (1.2%) who had a diagnosis of LVSD. Compared with standardised controls, the LVSD group had greater comorbidity, with the biggest difference found for seven or more conditions (odds ratio [OR] 4.10; 95% confidence interval (CI] = 3.90 to 4.32). Twenty-five physical conditions and six mental health conditions were significantly more prevalent in those with LVSD relative to standardised controls. Polypharmacy was higher in the LVSD group compared with controls, with the biggest difference found for ≥11 repeat prescriptions (OR 4.81; 95% CI = 4.60 to 5.04). However, these differences in polypharmacy were attenuated after controlling for the number of morbidities, indicating that much of the additional prescribing was accounted for by multimorbidity rather than LVSD per se. CONCLUSION: Extreme comorbidity and polypharmacy is significantly more common in patients with chronic heart failure due to LVSD. The efficient management of such complexity requires the integration of general and specialist expertise.
引用
- Baron-Franco B, McLean G, Mair FS, et al. Comorbidity and polypharmacy in chronic heart failure: a large cross-sectional study in primary care. Br J Gen Pract. 2017. PMID: 28396366. doi:10.3399/bjgp17X690533
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。